This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Viridian Therapeutics, Inc.
11/4/2026
Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics conference call. At this time, participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. As a reminder, this conference call is being recorded. I will now hand the call over to Greg Rossino, Senior Director of Investor Relations at Viridian. Please go ahead.
Thank you, operator, and good morning, everyone. Thank you for joining us to discuss Viridian's third quarter 2026 financial results and recent business updates. You can access the press release and the slides for today's call on the investor's page of our corporate website at viridiantherapeutics.com. Before we begin, I'd like to remind everyone that today's call and webcast will contain forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. A description of these risks can be found in the forward-looking statement section disclaimer in the press release and slides issued today, as well as our SEC filings, including our quarterly report on Form 10-Q. With me today are Steve Mahoney, our President and Chief Executive Officer, Tony Cassiano, our Chief Commercial Officer, and Seth Harmon, our Chief Financial Officer. Sean Wu, our Chief Business Officer, will join us for Q&A. With that, I'll turn the call over to Steve.
Thanks, Greg, and good morning, everyone. Thank you for joining us to discuss the results from our first quarter of Lombola launch in thyroid eye disease. As spelled out in our earnings release earlier this morning, it has been a very strong start, and the Viridian team has done another excellent job executing across the board. Lombola generated $24.7 million in net product revenue, and we had more than 100 patients on therapy as of September 30th. This is a very encouraging start to the launch and certainly has exceeded expectations. It is still early in the launch cycle, but we believe these results are a testament to Lombola's compelling product profile and the readiness and execution of our entire organization since day one of launch. Before we provide more color on the Lombola launch, I want to highlight the emerging Viridian pipeline, which we believe will drive the next chapter of Viridian's growth in autoimmune diseases. First, we're on track to submit our BLA for AllegraBART in the first quarter of 2027. ELLI is our next generation subcutaneous anti-IGF1R. Based on our phase three results, ELLI has the potential to further improve the TED patient experience, and we believe that it will encourage more patients to seek treatment with at-home self-administration as infrequently as every eight weeks. Later this quarter, we also look forward to sharing first in human results for VRDN008. 008 is a half-life extended FCRN inhibitor and is another example of a product candidate designed to reduce treatment burden with less frequent dosing while also providing sustained disease control. We're also making strong progress with our anti-TSHR product candidate, now called VRDN292, which we believe has the potential to be best in class. We expect to initiate a Phase I clinical trial with VRDN292 in Graves patients later this quarter. Together, these programs represent the future for Viridian, building a leadership position in TED and expanding our portfolio across other autoimmune diseases. With that, I'll turn it over to Tony to walk through the LUMBOA launch.
You're reading a preview of the VRDN Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing